Abstract

Nanostructured lipid carriers (NLC) have been widely studied as delivery systems for a variety of routes, including the skin. Their composition results in an imperfect lipid matrix, allowing increased drug encapsulation. Allopurinol (AP), a xanthine oxidase inhibitor, is characterized by low water solubility and high melting point, which has hampered its use through the topical route. In this work, AP was incorporated in a NLC formulation to enhance drug-carrier association and skin delivery as a topical approach to treat wounds. AP-NLC system was characterized in terms of size, charge, rheological behavior, and in vitro skin permeation. The in vitro cytotoxicity was evaluated using HaCaT cells. The wound healing efficacy of the AP-NLC formulation on animal skin lesions was evaluated in male Wistar rats. The AP-NLC presented a mean size of 193 ± 15 nm with a PdI of 0.240 ± 0.02, zeta potential values around −49.6 mV, and an encapsulation efficiency of 52.2%. The AP-NLC formulation presented an adequate profile to be used topically, since epidermal and dermal drug retention were achieved. No reduction in HaCaT cells viability was observed at the tested concentrations (AP < 10 μg/mL). The in vivo application of the AP-NLC formulation resulted in the regeneration of skin lesions when compared with non-treated controls.

Highlights

  • The selection of Nanostructured lipid carriers (NLC) components was based on literature reviews and on preliminary assays

  • Liquid lipid combination, which leads to the formation of an appropriate solid nanoparticle matrix, was chosen and the AP solubility in the lipids at 80 ◦ C was evaluated

  • It was possible to solubilize the maximum amount of AP in 2.5 g Precirol and 0.25 g Miglyol was

Read more

Summary

Introduction

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wound healing management has been extensively studied, since currently available approaches do not completely respond to the need of reducing the incidence of nonhealing wounds [1,2]. A successful healing system should be capable of accelerating the wound closure, reducing infection, and stimulating healing mechanisms, mimicking the extracellular matrix feature, moisture the wound, and reducing scar formation [3]. The development of effective novel wound therapies to better manage patients with chronic wounds is an intense area of research to identify the physiological and metabolic key players in wounds’

Objectives
Methods
Results
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call